10-K: Zynex Inc. Reports 2023 Financial Results, Highlights Growth and Strategic Initiatives

Zynex Inc. reports a 17% increase in revenue and a 29% increase in operating cash flow for 2023, alongside strategic investments in sales and product development.

Summary

• Zynex Inc. achieved a 17% increase in net revenue, reaching $184.3 million in 2023, compared to $158.2 million in 2022.
• The company's net income for 2023 was $9.7 million, a decrease from $17.0 million in 2022.
• Operating cash flows increased by 29% to $17.8 million in 2023.
• The company repurchased approximately $37.9 million worth of its common stock during the year.
• Zynex experienced a 43% increase in order growth, contributing to higher sales of both devices and consumable supplies.
• The company's working capital stood at $69.3 million at the end of 2023.
• The company has approximately 500 field sales representatives and aims to reach 600 by the end of 2024.
• Research and development expenses for ZMS operations were approximately $9.2 million in 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with strong revenue growth and strategic initiatives offset by a decrease in net income and identified material weaknesses in internal controls. The company's future outlook is positive, but there are risks that need to be addressed.

Positives

• The company experienced significant growth in order volume and revenue.
• Operating cash flow saw a substantial increase.
• Zynex is actively investing in its sales force and product development.
• The company has received several accolades, indicating strong market recognition.
• The company is progressing with clinical studies and regulatory submissions for its monitoring solutions.

Negatives

• Net income decreased from $17.0 million in 2022 to $9.7 million in 2023.
• The company identified material weaknesses in its internal controls over financial reporting.
• Sales and marketing expenses increased to 47% of revenue, up from 42% in the previous year.
• General and administrative expenses increased to 26% of revenue, up from 23% in the previous year.

Risks

• The company is subject to risks related to reimbursement from third-party payers.
• There are risks associated with the estimation of revenue, related refund liabilities, accounts receivable, and provider discounts.
• The company faces competition from other medical device companies.
• Reliance on sole suppliers and potential disruptions in the supply chain could adversely affect operations.
• The company is subject to various healthcare fraud and abuse laws and regulations.
• Cybersecurity threats and data breaches could lead to reduced revenue and increased costs.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company is subject to risks associated with international expansion.

Future Outlook

The company expects research and development expenses to increase in 2024 as the ZMS business expands and aims to have approximately 600 sales representatives by the end of 2024.

Management Comments

• The company is focused on expanding its sales force to address what it believes is an untapped market for electrotherapy products.
• The company is committed to providing healthcare professionals with alternatives to traditional opioid-based treatment programs.
• The company is continually adding new complementary products to its ZMI sales channel.

Industry Context

The company operates in the home electrotherapy market for pain management and rehabilitation, which is estimated to be a $500 million to $1 billion market. The company is positioned to benefit from the current opioid epidemic by offering non-pharmacological pain relief alternatives.

Comparison to Industry Standards

• The company competes with International Rehabilitative Sciences, Inc. d/b/a RS Medical, EMSI, and H-Wave.
• The company's growth in revenue and sales force expansion is notable compared to some smaller competitors.
• The company's focus on non-invasive pain management aligns with broader industry trends towards reducing opioid use.
• The company's development of advanced monitoring solutions positions it to compete with larger manufacturers in the patient monitoring space.

Related Party Transactions

• The disinterested members of the Board of Directors and Audit Committee approved the purchase of 300,000 shares of the Company's common stock from Thomas Sandgaard on May 10, 2023, and again on June 13, 2023.

Stakeholder Impact

• Shareholders may be impacted by the stock repurchase program and the company's financial performance.
• Employees may be impacted by the company's growth and expansion plans.
• Customers may benefit from the company's new products and services.
• Suppliers may be impacted by the company's supply chain management.

Next Steps

• The company plans to continue hiring field sales representatives, aiming for 600 by the end of 2024.
• The company will focus on increasing performance management standards for its sales force.
• The company will continue to refine the algorithms for the patented Relative Index for its fluid monitoring system.
• The company plans to pursue CE marking on several of its electrotherapy devices and its CM-1600 Zynex Fluid Monitoring System.
• The company anticipates submitting NiCO to the FDA for clearance in the first half of 2024.
• The company is in the process of developing and implementing remediation plans to address the material weakness in internal control over financial reporting.

Key Dates

Keywords

electrotherapy, pain management, medical devices, fluid monitoring, pulse oximetry, FDA clearance, revenue growth, stock repurchase, internal controls, sales force